Tobias Britzke

Tobias Britzke

Auto-generated profile, based on publicly available information

Tobias Britzke

Department of Experimental Animal Facilities and Biorisk Management, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2024 in Nature
Verified
Journal Article
Open access
PDF file
NHNico Joel Halwe
Nico Joel Halwe
KCKonner Robert Cool
Konner Robert Cool
ABAngele Breithaupt
Angele Breithaupt
JSJacob Schön
Jacob Schön
JTJessie D. Trujillo
Jessie D. Trujillo
JRJuergen A. Richt
Juergen A. Richt
In March 2024, highly pathogenic avian influenza virus (HPAIV) clade 2.3.4.4b H5N1 infections were reported in dairy cows in Texas, USA1. Rapid dissemination to more than 380 farms in 14 states followed2. Here we provide results of two independent clade 2.3.4.4b experimental infection studies evaluating the oronasal susceptibility to and transmission of a US H5N1 bovine isolate, genotype B3.13 (H5N1 B3.13), in calves, and the susceptibility of lactating cows following direct mammary gland inoculation of either H5N1 B3.13 or a current EU H5N1 wild bird isolate, genotype euDG (H5N1 euDG). Inoculation of the calves resulted in moderate nasal replication and shedding with no severe clinical signs or transmission to sentinel calves. In dairy cows, infection resulted in no nasal shedding, but severe acute infection of the mammary gland with necrotizing mastitis and high fever was observed for both H5N1 isolates. Milk production was rapidly and markedly reduced and the physical condition of the cows was severely compromised. Virus titres in milk rapidly peaked at 109 50% tissue culture infectious dose (TCID50) per ml, but systemic infection did not ensue. Notably, the adaptive mutation E627K emerged in the viral polymerase basic protein 2 (PB2) after intramammary replication of H5N1 euDG. Our data suggest that in addition to H5N1 B3.13, other HPAIV H5N1 strains have the potential to replicate in the udder of cows and that milk and milking procedures, rather than respiratory spread, are likely to be the primary routes of H5N1 transmission between cattle.

12 July 2024 in Nature Microbiology
Verified
Journal Article
Open access
PDF file
JSJacob Schön
Jacob Schön
GBGüliz Tuba Barut
Güliz Tuba Barut
BTBettina Salome Trüeb
Bettina Salome Trüeb
NHNico Joel Halwe
Nico Joel Halwe
IVInês Berenguer Veiga
Inês Berenguer Veiga
VTVolker Thiel
Volker Thiel
Approved vaccines are effective against severe COVID-19, but broader immunity is needed against new variants and transmission. Therefore, we developed genome-modified live-attenuated vaccines (LAV) by recoding the SARS-CoV-2 genome, including ‘one-to-stop’ (OTS) codons, disabling Nsp1 translational repression and removing ORF6, 7ab and 8 to boost host immune responses, as well as the spike polybasic cleavage site to optimize the safety profile. The resulting OTS-modified SARS-CoV-2 LAVs, designated as OTS-206 and OTS-228, are genetically stable and can be intranasally administered, while being adjustable and sustainable regarding the level of attenuation. OTS-228 exhibits an optimal safety profile in preclinical animal models, with no side effects or detectable transmission. A single-dose vaccination induces a sterilizing immunity in vivo against homologous WT SARS-CoV-2 challenge infection and a broad protection against Omicron BA.2, BA.5 and XBB.1.5, with reduced transmission. Finally, this promising LAV approach could be applicable to other emerging viruses.

9 August 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
NHNico Joel Halwe
Nico Joel Halwe
KCKonner Robert Cool
Konner Robert Cool
ABAngele Breithaupt
Angele Breithaupt
JSJacob Schön
Jacob Schön
JTJessie D. Trujillo
Jessie D. Trujillo
JRJuergen A. Richt
Juergen A. Richt
Summary: In March 2024, highly pathogenic avian influenza virus (HPAIV) clade 2.3.4.4b H5N1 infections in dairy cows were first reported from Texas, USA. Rapid dissemination to more than 190 farms in 13 states followed. Here, we provide results of two independent clade 2.3.4.4b experimental infection studies evaluating (i) oronasal susceptibility and transmission in calves to a US H5N1 bovine isolate genotype B3.13 (H5N1 B3.13) and (ii) susceptibility of lactating cows following direct mammary gland inoculation of either H5N1 B3.13 or a current EU H5N1 wild bird isolate genotype euDG (H5N1 euDG). Inoculation of the calves resulted in moderate nasal replication and shedding with no severe clinical signs or transmission to sentinel calves. In dairy cows, infection resulted in no nasal shedding, but severe acute mammary gland infection with necrotizing mastitis and high fever was observed for both H5N1 genotypes/strains. Milk production was rapidly and drastically reduced and the physical condition of the cows was severely compromised. Virus titers in milk rapidly peaked at 10 8 TCID 50 /mL, but systemic infection did not ensue. Notably, adaptive mutation PB2 E627K emerged after intramammary replication of H5N1 euDG. Our data suggest that in addition to H5N1 B3.13, other HPAIV H5N1 strains have the potential to replicate in the udder of cows and that milk and milking procedures, rather than respiratory spread, are likely the primary routes of H5N1 transmission between cattle.

30 October 2024 in npj Vaccines
Verified
Journal Article
Open access
PDF file
MLMartin Joseph Lett
Martin Joseph Lett
FOFabian Otte
Fabian Otte
DHDavid Hauser
David Hauser
JSJacob Schön
Jacob Schön
EKEnja Tatjana Kipfer
Enja Tatjana Kipfer
Thomas KlimkaitThomas Klimkait
Thomas Klimkait
Vaccines have played a central role in combating the COVID-19 pandemic, but newly emerging SARS-CoV-2 variants are increasingly evading first-generation vaccine protection. To address this challenge, we designed “single-cycle infection SARS-CoV-2 viruses” (SCVs) that lack essential viral genes, possess distinctive immune-modulatory features, and exhibit an excellent safety profile in the Syrian hamster model. Animals intranasally vaccinated with an Envelope-gene-deleted vaccine candidate were fully protected against an autologous challenge with the SARS-CoV-2 virus through systemic and mucosal humoral immune responses. Additionally, the deletion of immune-downregulating viral genes in the vaccine construct prevented challenge virus transmission to contact animals. Moreover, vaccinated animals displayed neither tissue inflammation nor lung damage. Consequently, SCVs hold promising potential to induce potent protection against COVID-19, surpassing the immunity conferred by natural infection, as demonstrated in human immune cells.

10 March 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
JSJacob Schön
Jacob Schön
NHNico Joel Halwe
Nico Joel Halwe
TBTobias Britzke
Tobias Britzke
ABAngele Breithaupt
Angele Breithaupt
LULorenz Ulrich
Lorenz Ulrich
DHDavid Hauser
David Hauser
A next-generation SARS-CoV-2 vaccine must address the currently inadequate prevention of virus transmission, particularly against emerging variants of concern, a challenge that none of the licensed commercial vaccines fully meet. Effective control of respiratory pandemics necessitates vaccines that 1) can be rapidly adapted, 2) have high patient compliance with simple and non-invasive administration, and 3) block transmission in a virus challenge. We describe here the characterization of an updated single-cycle SARS-CoV-2 vaccine candidate (scVac), engineered as a replication-defective virus with targeted deletions of the E gene and ORF6 and ORF7a, along with a truncation of ORF3a. The candidate carries an Omicron XBB.1.5 Spike (scVac XBB ), maintaining all essential antigenic properties. The vaccine demonstrated an excellent safety profile in K18-hACE2 transgenic mice, the most sensitive virulence model, with no clinical signs or adverse events observed. In the Syrian hamster model, potent systemic and mucosal immune responses were induced, along with a strong neutralizing antibody response. Notably, there was no virus transmission to co-housed naïve animals, which outperforms a bivalent Omicron mRNA vaccine reference. Our results demonstrate that scVac XBB -induced immunity not only prevents disease but also effectively blocks transmission. Furthermore, the successful introduction of the XBB.1.5 Spike protein into the scVac platform demonstrates the pipeline’s ability to adapt quickly to any emerging variant. These findings highlight the potential of this single-cycle concept as a next-generation COVID-19 vaccine, offering robust protection with a strong safety profile.

23 September 2026 in iScience
Verified
Journal Article
Open access
TBTobias Britzke
Tobias Britzke
JSJacob Schön
Jacob Schön
NHNico Joël Halwe
Nico Joël Halwe
LULorenz Ulrich
Lorenz Ulrich
JKJana Kochmann
Jana Kochmann
ABAngele Breithaupt
Angele Breithaupt
Respiratory viruses frequently initiate infection in the nasal mucosa, where virus-host interactions shape disease progression and transmission. Yet this site remains undercharacterized due to anatomical and technical challenges. Spatially resolved technologies are limited by cost and complexity, leaving most studies reliant on bulk or descriptive approaches lacking spatial context. We present a framework for spatially resolved investigation of infections in the nasal cavity. Using wild-type SARS-CoV-2 and two live-attenuated vaccines (OTS-206, OTS-228) as model viruses in Syrian hamsters, we integrate standardized sampling, histopathology, immunohistochemistry, multiplex RNA in situ hybridization, and quantitative image analysis across spatial scales, including tissue, single-cell, and subcellular resolution. We identified distinct infection patterns and graduated tissue damage from wild-type to OTS-228. Despite limited infection, OTS-228 induces a robust tissue-preserving immune response. Subcellular analysis shows that both vaccines exhibit a primarily cytoplasmic distribution of host antiviral transcripts, whereas WT infection is characterized by predominantly nuclear RNA localization.